Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

47
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
47
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

778
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
778
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

71
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
71
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

401
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
401
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

53
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
53
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

134
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
134

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply: To PMID 23257375.

JACC. Cardiovascular interventions·2013
Same author

Can bioabsorbable scaffolds be used in calcified lesions?

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2013
Same author

Impact of residual chronic total occlusion of right coronary artery on the long-term outcome in patients treated for unprotected left main disease: the Milan and New-Tokyo registry.

Circulation. Cardiovascular interventions·2013
Same author

[Intra-arterial thrombolysis facilitated by ultrasound in submassive pulmonary embolism: first documented case report in Italy].

Giornale italiano di cardiologia (2006)·2013
Same author

Renal denervation in a patient with two renal accessory arteries: a case report.

Blood pressure·2013
Same author

The CABG SYNTAX Score - an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the SYNTAX Left Main Angiographic (SYNTAX-LE MANS) substudy.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2013

Related Experiment Video

Updated: Oct 19, 2025

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.8K

Insights Into Coronary Sinus Reducer Non-Responders.

Francesco Ponticelli, Arif A Khokhar, Stefano Albani

  • 1Interventional Cardiology Unit, GVM Care & Research Maria Cecilia Hospital, Via Madonna di Genova, 1, 48033 Cotignola RA, Italy. giannini_fra@yahoo.it.

The Journal of Invasive Cardiology
|September 20, 2021
PubMed
Summary

The coronary sinus (CS) reducer helps refractory angina, but 15-30% of patients don't respond. This review explores six key reasons for treatment failure, aiming to improve outcomes for non-responders.

Keywords:
chronic coronary diseaseinterventional cardiologypercutaneous coronary interventionrefractory angina

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.4K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.5K

Related Experiment Videos

Last Updated: Oct 19, 2025

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.8K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.4K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.5K

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Vascular Devices

Background:

  • Refractory angina impacts patients with advanced coronary artery disease and microvascular dysfunction.
  • Current treatments offer limited options for this patient group.
  • The coronary sinus (CS) reducer is a device implanted in the CS to manage chronic refractory angina.

Purpose of the Study:

  • To review the mechanisms behind poor response to coronary sinus (CS) reducer therapy.
  • To identify factors contributing to treatment failure in patients with refractory angina.
  • To highlight areas for improvement to reduce the number of non-responders.

Main Methods:

  • Literature review of mechanisms explaining non-response to CS reducer therapy.
  • Analysis of factors including patient selection, cardiac venous anatomy, and device-related issues.
  • Discussion of coronary artery disease characteristics and myocardial ischemia levels.

Main Results:

  • Between 15% and 30% of patients do not respond to CS reducer therapy.
  • Six primary mechanisms for non-response are identified: inappropriate patient selection, cardiac venous heterogeneity, CS size, incomplete device endothelialization, coronary artery disease phenotype/progression, and limited baseline myocardial ischemia.
  • These factors collectively explain the variability in treatment outcomes.

Conclusions:

  • Understanding the mechanisms of non-response is crucial for optimizing CS reducer therapy.
  • Addressing patient selection, anatomical variations, and device performance can potentially improve outcomes.
  • Further research is needed to mitigate the burden of non-responders and enhance quality of life for angina patients.